Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

Prior treatment

• Require combined chemotherapy other than Eribulin;
• Stroke or cardiovascular and cerebrovascular events within 6 months before enrollment;
• Previous hematopoietic stem cell or bone marrow transplantation;
• Previous G-CSF treatment in the last 2 weeks;

Other illness

• Diagnosed other malignant disease besides breast cancerwithin 5 years before the first dose (excluding radical skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or radical resection);
• Allergic to the study drug or the ingredients;

Other

• Main organ function not good enough;
• Bone marrow invasion;
• QTcF \> 480 msec ( screening period) and QTcF\> 500 msec for patients with ventricular pacemaker implantation;
• Any other situation where the researcher considers the patient not suitable to participate in this study.

• ≥18 years old , no limitation of gender;
• locally advanced or metastatic triple-negative breast cancer;
• have received at least two prior chemotherapy regimens(The recurrence of the last adjuvant chemotherapy is counted one line within 12 months after surgery);
• At least one measurable lesion according to RECIST version 1.1;
• The laboratory tests meet the following criteria:
  • Hemoglobin: ≥ 100 g / L (female), 110g / L (male) Neutrophil count : ≥2×10\^9/L Platelet count: ≥100×10\^9/L Creatinine：≤15mg / L or creatinine clearance (CrCl) ≥60 mL/min (Cockcroft-Gault formula); Total bilirubin：≤1.5× upper limit of normal (ULN) Alutamate aminotransferase (ALT) and glutamate aminotransferase (AST)≤ 3 ×ULN or 5 ×ULN (for patients with liver metastases) Albumin: ≥ 30 g / L;
• Eastern Cooperative Oncology Group (ECOG) score \[0-1\] points;
• The expected survival period is ≥3 months;
• During the screening period, all female with potential fertility must have negative serum pregnancy tests and reliable contraception after signing the informed consent form until 3 months after the last dose;
• Comprehend and voluntarily sign the informed consent form;